Goldman Sachs upgraded Roche to 'neutral' from 'sell,' citing positive late-stage trial results for fenebrutinib in multiple sclerosis. The pharmaceutical giant saw a 33% share increase since November 2025, driven by promising data from the FENhance-2 trial and a fenebrutinib study in primary progressive MS. Goldman Sachs also noted early positive results from the lidERA trial of giredestrant in adjuvant breast cancer, contributing to an improved outlook. This shift reflects reduced risk and enhanced growth prospects for Roche.

The upgrade comes after several setbacks, including negative outcomes from high-dose Ocrevus trials and studies on astegolimab and giredestrant. Despite the positive momentum, Goldman Sachs is cautious, attributing the recent share price surge to already reflected upside. The brokerage raised its 12-month price target for Roche to CHF365, implying a modest 6% upside from the current share price. This valuation increase is based on a higher 12-month forward price-to-earnings multiple of 16x, up from 12.5x, aligning with current consensus valuations.

Looking ahead, Goldman Sachs forecasts that Roche's improved outlook is driven by expected contributions from giredestrant and fenebrutinib, along with continued performance from existing products like Vabysmo and Ocrevus. The brokerage also highlighted potential risks, including upcoming Phase 3 data for giredestrant and additional fenebrutinib trials. Competitive uncertainty in Roche's obesity portfolio and generic erosion on some established products remain concerns. Despite these risks, the upgrade signals a more optimistic view of Roche's future prospects.

For investors, Roche's shift to 'neutral' suggests a more balanced risk-reward profile. The positive trial results and improved growth outlook offer a glimmer of hope, but the recent share price increase has already priced in much of the potential upside. Investors should watch for upcoming trial results and monitor Roche's ability to deliver on its improved forecasts, especially for key products like giredestrant and fenebrutinib.